Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Bosutinib Tablets, 100 mg and 500 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Bosutinib Tablets, 100 mg and 500 mg".